“…After independent review, 24 publications dealing with prognostic value of PLC in patients with lung cancer were considered to be eligible for inclusion in the analysis . Of these publications, one was excluded because it did not allow the calculation of HR [26], four were excluded because no survival data in negative PLC group were available [6,[27][28][29], three were excluded because the same authors published several reports on the same patients, and only the best-quality study was considered [30][31][32], three were excluded because they did not provide sufficient data to perform a quantitative aggregation [5,33,34]. Subsequently, 15 articles [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] were available for analysis of the PLC prognostic significance; the clinical characteristics of these studies, along with ELCWP scores, are outlined in Table 1, and the ELCWP scores in detail are shown in Appendix Table 1 (provided in supplemental material on the Web).…”